Gastrointestinal / Immunology
Artizan is developing a portfolio of compounds to treat inflammatory bowel disease (IBD), which is comprised of Crohn’s Disease (CD) and ulcerative colitis (UC).
IBD refers to a set of diseases that cause chronic inflammation of the small and/or large intestines with roughly 45% of cases defined as CD and 55% are UC.1 As of 2017, the global prevalence of IBD is between 6-8 million cases2, approximately 3 million of which are in the United States3. CD and UC can occur at any age, but diagnoses are most frequent between the ages of 15 and 35. IBD is a complex condition for which currently available therapies are only moderately effective, many patients fail to achieve a deep, long-lasting remission. While there have been tremendous advances in IBD therapies, approximately 30% of patients are unresponsive to initial biologics therapy and, even among responsive patients, up to 10% stop responding to treatment annually. For more information about IBD, please visit the Crohn’s & Colitis Foundation.
1 Hazel K, O’Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis. 2020;11:2040622319899297. Published 2020 Feb 5. DOI: 10.1177/2040622319899297
2 GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):17-30. doi: 10.1016/S2468-1253(19)30333-4. Epub 2019 Oct 21. PMID: 31648971; PMCID: PMC7026709.
3 Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years — United States, 2015. MMWR Morb Mortal Wkly Rep 2016;65:1166–1169. DOI: http://dx.doi.org/10.15585/mmwr.mm6542a3